This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 1989 Feb;21(1 Pt 3):3022-4.

Genetic analysis of the anti-leukemic effect of mixed allogeneic bone marrow transplantation

M Sykes¹, D H Sachs

Affiliations

PMID: 2650417

Genetic analysis of the anti-leukemic effect of mixed allogeneic bone marrow transplantation

M Sykes et al. Transplant Proc. 1989 Feb.

. 1989 Feb;21(1 Pt 3):3022-4.

Authors

M Sykes¹, D H Sachs

Affiliation

¹ Transplantation Biology Section, National Cancer Institute, Bethesda, MD 20892.

PMID: 2650417

No abstract available

PubMed Disclaimer

Similar articles

Graft-versus-leukemia effect using mixed allogeneic bone marrow transplantation.
Sykes M, Bukhari Z, Sachs DH. Sykes M, et al. Bone Marrow Transplant. 1989 Sep;4(5):465-74. Bone Marrow Transplant. 1989. PMID: 2790325
Histocompatibility influence in allogeneic marrow transplantation therapy of murine viral leukemia. I.--Studies of the relative influence of major versus minor histocompatibility determinants.
Meredith RF, Okunewick JP, Raikow RB, Brozovich BJ, Seeman PR, Magliere KC. Meredith RF, et al. Biomedicine. 1981 Feb;34(1):11-7. Biomedicine. 1981. PMID: 7013840
A nonlethal conditioning approach to achieve durable multilineage mixed chimerism and tolerance across major, minor, and hematopoietic histocompatibility barriers.
Colson YL, Wren SM, Schuchert MJ, Patrene KD, Johnson PC, Boggs SS, Ildstad ST. Colson YL, et al. J Immunol. 1995 Nov 1;155(9):4179-88. J Immunol. 1995. PMID: 7594573
Adaptive phenomena in bone marrow transplantation.
Goujet-Zalc C, Ilbery PL. Goujet-Zalc C, et al. Exp Hematol. 1973;1(1):3-10. Exp Hematol. 1973. PMID: 4154047 Review. No abstract available.
Achieving alloengraftment without graft-versus-host disease: approaches using mixed allogeneic bone marrow transplantation.
Sykes M, Sharabi Y, Sachs DH. Sykes M, et al. Bone Marrow Transplant. 1988 Sep;3(5):379-86. Bone Marrow Transplant. 1988. PMID: 3056545 Review.

See all similar articles

Cited by

Host MHC class II+ antigen-presenting cells and CD4 cells are required for CD8-mediated graft-versus-leukemia responses following delayed donor leukocyte infusions.
Chakraverty R, Eom HS, Sachs J, Buchli J, Cotter P, Hsu R, Zhao G, Sykes M. Chakraverty R, et al. Blood. 2006 Sep 15;108(6):2106-13. doi: 10.1182/blood-2006-03-007427. Epub 2006 Jun 6. Blood. 2006. PMID: 16757687 Free PMC article.
Graft-versus-leukemia activity after bone marrow transplantation does not require graft-versus-host disease.
Glass B, Uharek L, Gassmann W, Focks B, Bolouri H, Loeffler H, Mueller-Ruchholtz W. Glass B, et al. Ann Hematol. 1992 Jun;64(6):255-9. doi: 10.1007/BF01695466. Ann Hematol. 1992. PMID: 1637877
Interleukin 2 prevents graft-versus-host disease while preserving the graft-versus-leukemia effect of allogeneic T cells.
Sykes M, Romick ML, Sachs DH. Sykes M, et al. Proc Natl Acad Sci U S A. 1990 Aug;87(15):5633-7. doi: 10.1073/pnas.87.15.5633. Proc Natl Acad Sci U S A. 1990. PMID: 2377601 Free PMC article.
Graft-versus-host disease can be separated from graft-versus-lymphoma effects by control of lymphocyte trafficking with FTY720.
Kim YM, Sachs T, Asavaroengchai W, Bronson R, Sykes M. Kim YM, et al. J Clin Invest. 2003 Mar;111(5):659-69. doi: 10.1172/JCI16950. J Clin Invest. 2003. PMID: 12618520 Free PMC article.

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information